| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10486107 | Value in Health | 2015 | 9 Pages |
Abstract
In the unadjusted ITT analysis, cinacalcet does not represent a cost- effective use of health care resources when applying a willingness-to-pay threshold of $100,000 per QALY. When using the covariate-adjusted ITT treatment effect, which represents the least biased estimate, however, cinacalcet is a cost-effective therapy for patients with moderate-to-severe sHPT on hemodialysis.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Vasily PhD, Glenn M. MD, MPH, Christopher N. MS, Bastian MD, Patrick S. MD, Andrew H. DPhil,